Exclusion Reasons Presumption of Long- Term Non-Acute Administration C9399 Unclassified Drugs or

Similar documents
Descriptor Brand Name. Alprostadil, Caverject, Edex, Prostin VR Pediatric. Calcimar, Miacalcin

SELF-ADMINISTERED MEDICATIONS LIST

MDwise Self-Administered Codes for Medical

RAHF PFM ALPHANINE SD COAGULATION FACTOR IX J7193 COAGULATION FACTOR IX (RFIXFC)

List of Designated High-Cost Drugs

Self-Injected Medications and Disposal Recommendations

METABOLIC, IMMUNE DISORDERS OR INHERITED RARE DISEASE ALPHA-1 PROTEINASE INHIBITORS ARANESP BLOOD CELL DEFICIENCY ARANESP ARCALYST

Formulary Changes. One mission: you TABLE A. FORMULARY CHANGES 7/1/2018: Commercial 3-Tier Formulary. Commercial 4-Tier Formulary

LIST OF DRUGS THAT MAY BE COVERED UNDER YOUR MEDICAL BENEFIT

5-ASA. Products Affected DIPENTUM 250 MG CAPSULE LIALDA 1.2 GRAM TABLET,DELAYED RELEASE. Details

5-ASA. Products Affected. Details. Dipentum 250 mg capsule. Lialda 1.2 gram tablet,delayed release

Granite Alliance Insurance Company (PDP) 2018 Step Therapy Criteria Last Updated: 10/23/18

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process

STEP THERAPY CRITERIA

PRESCRIPTION DRUGS REQUIRING PRIOR AUTHORIZATION

Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary

Specialty Drugs. The following is a list of medications that are considered to be specialty drugs. Specialty drugs

RPCC Pharmacy Forum. The Type 2 Diabetes Issue. Type 2 Diabetes: The Basics

TRICARE Uniform Formulary. Pre-Authorization Requirements

Oregon Health Plan prescription benefit updates

What the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin

Specialty Drugs. The specialty drug list below is effective June 5, 2018 and is subject to change at any time.

Initiating Injectable Therapy in Type 2 Diabetes

FARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority

Objectives. How Medicine Works to Control Blood Sugar Levels. What Happens When We Eat? What is diabetes? High Blood Glucose (Hyperglycemia)

PRESCRIPTION DRUGS REQUIRING PRIOR AUTHORIZATION

2018 BCN Advantage Prior Authorization Criteria Last updated: November, 2017

2018 BCN Advantage Prior Authorization Criteria Last updated: April, 2018

Specialty Pharmacy Pipeline

Regulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)

Cosentyx. Cosentyx (secukinumab) Description

March 2017 Pharmacy & Therapeutics Committee Decisions

DIABETES (1 of 5) Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10. Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10 $0 $0 $0

1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.

MedStar Medicare Choice Pharmacy Services

Pharmacologic Agents for Treatment of Type 2 Diabetes

Regulatory Status FDA-approved indications: Entyvio is an α4β7integrin receptor antagonist indicated for: (1)

Prior Authorization Program Information (Effective April 1st, 2018)

Collaborative Practice Agreement

Pharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17

Prescription benefit updates Large group

Step Therapy Criteria 2019

Management of Type 2 Diabetes Mellitus. Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism

Regulatory Status FDA-approved indication: Orencia is a selective T cell co-stimulation modulator indicated for: (1)

CIMZIA (certolizumab pegol)

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Prescription Drug Benefit Rider

Mountain Health Trust/WV Health Bridge

ACTEMRA (tocilizumab)

Drug Bill As Unit Common Directions Common Day Supply Common Billing Errors Oral Tablets/Capsules

Prescription Drug Benefit Rider V

Thank you for your request for information that has been processed under reference number

HEALTH SHARE/PROVIDENCE (OHP)

Otezla. Otezla (apremilast) Description

Stelara. Stelara (ustekinumab) Description

What s New in Type 2 Diabetes? 2018 Diabetes Updates

This program applies to Commercial, GenPlus and Health Insurance Marketplace formularies.

OptumRx Focused Utilization Management Program

HEALTHTEAM ADVANTAGE 2018 Step Therapy Criteria

Technician Tutorial: Dispensing Insulin and Other Injectable Meds

HEALTHTEAM ADVANTAGE 2018 Step Therapy Criteria

Xeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description

Images have been removed from the PowerPoint slides in this handout due to copyright restrictions. Insulins. Rapid Short Intermediate Long Mix

These programs and quantity limitations may not apply. Check your certificate or other plan information for benefit details.

New Billing Guidelines for Home Infusion, Enteral and Parenteral Therapies Home Infusion Fee Schedule Effective July 1, 2009

DPP4 INHIBITORS. Details. Step Therapy Criteria Health Alliance Plan 2019 Date Effective: 04/01/2019

What s New in Type 2 Diabetes? 2018 Diabetes Updates

Injectable Therapies in Diabetes

5-ASA. Products Affected Dipentum 250 mg capsule. Details. Lialda 1.2 gram tablet,delayed release

DPP4 INHIBITORS. Products Affected Step 2: Janumet 50 mg-1,000 mg tablet Janumet 50 mg-500 mg tablet Januvia 100 mg tablet Januvia 25 mg tablet

TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations

Diabetes Update: Intensifying Insulin Therapy Nuts, Bolts and Other Items

See Important Reminder at the end of this policy for important regulatory and legal information.

RHEUMATOID ARTHRITIS DRUGS

Making Sense of New DM Therapies and Technologies

Premixed Insulin for Type 2 Diabetes. a gu i d e f o r a d u lt s

!"#$%&%'(!)*+'(,(&)%-!'(.#!%('"./0%(( /1#).!(&2()!(((

UPMC for You Pharmacy and Therapeutics Committee Meeting April 7, 2014 meeting

Cimzia. Cimzia (certolizumab pegol) Description

Clinical Policy: Natalizumab (Tysabri) Reference Number: ERX.SPA.162 Effective Date:

Injectable Therapies in Diabetes

DRUGS REQUIRING PRIOR AUTHORIZATION

Step Therapy Requirements. Effective: 12/01/2016

Blue Cross and Blue Shield of Minnesota GenRx Formulary Updates

Physician Drug Reference Chart for Diabetes Antidiabetic Medications

DIFICID. Products Affected Step 2: DIFICID TABLET 200 MG ORAL. Details

CENTENE PHARMACY & THERAPEUTICS COMMITTEE SECOND QUARTER 2017 AMBETTER GUIDELINE SUMMARY. Revision Summary or Description

INSULIN OVERVIEW. Type Brand Name Onset Peak Duration Role in glucose management Page Rapid-Acting lispro min. 3-5 hrs min.

Clinical Policy: Natalizumab (Tysabri) Reference Number: CP.PHAR.259 Effective Date: Last Review Date: Line of Business: Medicaid

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

Injectable Drugs Requiring Pre-Service Approval

TABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations

Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases

Transcription:

Noridian Healthcare Solutions, LLC Jurisdiction F Part B Self-Administered Drug (SAD) Exclusion List (A53033); Effective 8/7/2017 The following medications are considered self-administered and are not payable under Medicare Part B. Coverage may be provided under Medicare Part D. The most current version of this list may be accessed at med.noridianmedicare.com under Policies. The Noridian Contractor Medical Directors (CMDs) review the list on an ongoing basis and may update and republish at their discretion. Code Generic Name Brand Name Effective Date Apparent On Its Face Exclusion Reasons Presumption of Long- Term Non-Acute Administration Tanzeum (albiglutide SQ) 6/4/2015 X X Myalept (metreleptin) 6/4/2015 X X Signifor (pasireotide) 6/4/2015 X X Rebif (interferon beta 1a) 6/4/2015 X X Bydureon (exanatide XR) 6/4/2015 X X Cosentyx (secukinumab) 6/4/2015 X X Praluent (alirocumab) 11/24/2015 X Repatha (evolucumab) 11/24/2015 X Trulicity (dulaglutide) Acceptable Evidentiary Criteria Available

C9399 Unclassified Drugs or Otrexup, Rasuvo (methotrexate solution auto-injector nonchemotherapeutic) Natpara (parathyroid hormone) Plegridy (pedinterferon beta-1a) Toujeo (insulin glargine injection) Byetta (exenatide) Erelzi (etanercept-szzs) 12/6/2016 X Strensiq (asfotase-alfa) 2/28/2017 X Zinbryta (daclizumab) 2/28/2017 X Taltz (ixekizumab) 2/28/2017 X Amjevita (adalimumab-atto) 2/28/2017 X Dupixent (dupilumab) 8/7/2017 X Siliq (brodalumab) 8/7/2017 X J0135 Injection, Adalimumab, 20 Mg Humira 11/1/2003 X X J0270 Injection, Alprostadil, 1.25 Alprostadil, Caverject, Edex, 1/15/2003 X X Mcg (Code May Be Used For Prostin VR Pediatric Medicare When Drug Administered Under The

J0364 J0630 Injection, Apomorphine Hydrochloride, 1 Mg Injection, Calcitonin Salmon, Up To 400 Units Apokyn 6/4/2015 X X Calcimar, Miacalcin, Osteocalcin, Salmonine, Fortical 1/15/2003 X X H. P. Acthar 6/26/2013 X X J0800 Injection, Corticotropin, Up To 40 Units J1324 Injection, Enfuvirtide, 1 Mg Fuzeon 5/1/2004 X X J1438 Injection, Etanercept, 25 Mg Enbrel 1/15/2003 X X (Code May Be Used For Medicare When Drug Administered Under The J1559 Injection, Immune Globulin Hizentra 2/15/2011 X X (Hizentra), 100 Mg J1595 Injection, Glatiramer Acetate, Copaxone 5/1/2004 X X 20 Mg J1675 Injection, Histrelin Acetate, 10 Supprelin LA 7/15/2006 X X Micrograms J1744 Injection, Icatibant, 1 Mg Firazyr 7/31/2012 X X J1815 Injection, Insulin, Per 5 Units Humalog, Humalog Mix 11/1/2003 X X 50/50, Humulin N. Humulin R, Lantus, Levemir, Novolin 70/30, Novolin N. Novolin R. Novolog, Novolog Flexpen, Novolog Penfill J1817 Insulin For Administration Through Dme (I.E., Insulin Pump) Per 50 Units Humalog, Humulin R, Novolin R, Novolog, Novolog Flexpen, Novolog Penfill 1/15/2003 X X J1830 Injection, Interferon Beta-1b, 0.25 Mg (Code May Be Used Betaseron 1/15/2003 X X

For Medicare When Drug Administered Under The J2170 Injection, Mecasermin, 1 Mg Increlex, Iplex 4/15/2007 X X J2212 Injection, Methylnaltrexone, Relistor 9/30/2013 X X J2354 0.1 Mg Injection, Octreotide, Non- Depot Form For Subcutaneous Or Intravenous Injection, 25 Mcg Sandostatin, Ocreotide Acetate 10/15/2005 X J2440 Injection, Papaverine Hcl, Up Papaverine HCL 11/1/2003 X X To 60 Mg J2940 Injection, Somatrem, 1 Mg Protropin 1/15/2003 X X J2941 Injection, Somatropin, 1 Mg Humatrope, Genotropin, Omnitrope, Saizen, Zorbtive, Zomacton, Norditropin, Nutropin 1/15/2003 X X J3030 Injection, Sumatriptan Succinate, 6 Mg (Code May Be Used For Medicare When Drug Administered Under The Imitrex 1/15/2003 X X J3110 Injection, Teriparatide, 10 Mcg Forteo 11/1/2003 X J3355 Injection, Urofollitropin, 75 Iu Metrodin, Bravelle, Fertinex 4/15/2007 X X J3490 Unclassified Drugs Peginterferon Alfa 2-b, 6/26/2013 X X Sylatron, Pegintron J3490 Unclassified Drugs Kynamro (mipomersen 6/26/2016 X X sodium) J3490 Unclassified Drugs Pramlintide acetate, Symlin, SymlinPen 60, SymlinPen 4/1/2006 X X

120 J3490 Unclassified Drugs Byetta (exenatide) 4/1/2006 X X J3490 Unclassified Drugs Egrifta, Tesamorelin Acetate 9/30/2013 X X J3490 Unclassified Drugs Trimix 9/30/2013 X X J3490 Unclassified Drugs Victoza, Saxenda, Liraglutide 9/30/13 X X GLP-1 J3490 Unclassified Drugs Tanzeum (albiglutide SQ) 6/4/2015 X X J3490 Unclassified Drugs Myalept (metreleptin) 6/4/2015 X X J3490 Unclassified Drugs Signifor (pasireotide) 6/4/2015 X X J3490 Unclassified Drugs Rebif (interferon beta 1a) 6/4/2015 X X J3490 Unclassified Drugs Bydureon (exanatide XR) 6/4/2015 X X J3490 Unclassified Drugs Cosentyx (secukinumab) 6/4/2015 X X J3590 Unclassified Biologics Praluent (alirocumab) 11/24/2015 X J3590 Unclassified Biologics Repatha (evolucumab) 11/24/2015 X J3590 Unclassified Biologics Trulicity (dulaglutide) J3590 Unclassified Biologics Otrexup, Rasuvo (methotrexate solution auto-injector nonchemotherapeutic) J3590 Unclassified Biologics Natpara (parathyroid hormone) J3590 Unclassified Biologics Plegridy (pedinterferon beta-1a) J3590 Unclassified Biologics Toujeo (insulin glargine injection) J3590 Unclassified Biologics Pegvisomant Somavert 5/1/2004 X X J3590 Unclassified Biologics Pegasys, Roferon-A 5/1/2005 X X (peginterferon Alfa-2a) J3590 Unclassified Biologics Kineret (anakinra) 10/15/2005 X X J3590 Unclassified Biologics Simponi (golimumab) 9/30/2013 X X J3590 Unclassified Biologics Orencia (abatacept) 9/30/2013 X X J3590 Unclassified Biologics Erelzi (etanercept-szzs) 12/6/2016 X J3590 Unclassified Biologics Strensiq (asfotase-alfa) 2/28/2017 X

J3590 Unclassified Biologics Zinbryta (daclizumab) 2/28/2017 X J3590 Unclassified Biologics Taltz (ixekizumab) 2/28/2017 X J3590 Unclassified Biologics Amjevita (adalimumab-atto) 2/28/2017 X J3590 Unclassified Biologics Dupixent (dupilumab) 8/7/2017 X J3590 Unclassified Biologics Siliq (brodalumab) 8/7/2017 X J9212 Injection, Interferon Alfacon- Infergen 11/1/2003 X X 1, Recombinant, 1 Microgram J9213 Injection, Interferon, Alfa-2a, Roferon-A 11/1/2003 X X Recombinant, 3 Million Units J9216 Injection, Interferon, Gamma 1-B, 3 Million Units Actimmune 1/15/2003 X X J9218 Leuprolide Acetate, Per 1 Mg Leuprolide Acetate inj 1/15/2003 X X Q0515 Injection, Sermorelin Acetate, Geref 4/15/2007 X X 1 Microgram Q3027 Injection, Interferon Beta-1a, Avonex, Avonex Pen 6/4/2015 X X 1 Mcg For Intramuscular Use Q3028 Injection, Interferon Beta-1a, 1 Mcg For Subcutaneous Use N/A 6/4/2015 X X Visiant conducts organization determinations and reconsiderations on behalf of Premera Blue Cross.